Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
or on the link below. The standard treatment paradigm for muscle invasive bladder cancer has been neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. However, efforts are ongoing ...
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...
As of the April 20, 2026, data cut-off, 82 patients had been treated, and 72 had completed primary response evaluation. Dr.
Low-Dose Versus Standard-Dose Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multicenter Randomized Phase III Trial Among 343 patients analyzed, 217 (63.3%) had ...
Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy with pelvic lymph node dissection has been the standard of care for muscle-invasive bladder cancer for decades. The advent of ...
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients. Primary urothelial cancer has variable ...
Loqtorzi significantly improved progression-free and overall survival in HER2-expressing advanced urothelial carcinoma compared to chemotherapy. The study demonstrated a higher overall response rate ...
Background More than 429,000 patients worldwide are diagnosed with bladder cancer each year and muscle-invasive bladder cancer has an especially poor outcome. The median age at diagnosis is over 70 ...
Conducting Clinical Research in Low Research Resource Countries: Lessons Learned From the International Registry of Men With Advanced Prostate Cancer Study in Nigeria A retrospective study was ...
Urothelium is the term for the mucous membrane that lines the urinary tract. This includes the renal pelvis, ureter, urinary bladder and the upper part of the urethra. In the vast majority of cases, ...
Junshi Biosciences receives approval of toripalimab NDA from NMPA for first-line treatment of HER2 expressing urothelial carcinoma: Shanghai Saturday, May 23, 2026, 17:00 Hrs [IST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results